Cinacalcet
Product Images NDC 43598-369

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Cinacalcet (NDC 43598-369). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Label for Cinacalcet Tablets 30 mg by Dr. Reddys Laboratories Inc featuring the product name, strength, tablet count of 30, storage instructions, and a barcode. The label includes the NDC number 43598-367-30 and indicates the tablets are film-coated.*

FDA Label Image

Container2 (Container2)

Cinacalcet Tablets 60 mg label from Dr. Reddys Laboratories Inc. The label shows a 30-tablet count, includes the NDC number 43598-368-30, and details the active ingredient content per film-coated tablet. The label also provides storage instructions, barcode, and manufacturer information. The design features blue and red text on a white background with a red semicircle graphic.*

FDA Label Image

Container3 (Container3)

Label for Cinacalcet 90 mg tablets by Dr. Reddys Laboratories Inc. The label shows a tablet count of 30 tablets. It includes dosage strength and storage instructions, along with a barcode and NDC number 43598-369. The label has a white and gold design with blue and gold text.*

FDA Label Image

Figure1 (Figure1)

A line graph depicting changes in parathyroid hormone (PTH) levels (pg/mL) over 26 weeks comparing Cinacalcet (red line) to placebo (black dashed line). The x-axis represents weeks, and the y-axis represents PTH levels, with error bars indicating variability at each time point.*

FDA Label Image

Figure2 (Figure2)

A line graph comparing plasma concentration of phosphorus (Px in mg/dL) over 26 weeks between Cinacalcet and placebo groups. The X-axis represents time in weeks, while the Y-axis shows phosphorus concentration. Cinacalcet group data is shown with a red solid line with markers, and placebo is shown with a black dashed line. Error bars indicate variability at each time point.*

FDA Label Image

Figure3 (Figure3)

A line chart showing calcium levels (mg/dL) over a timeline in weeks for patients with parathyroid carcinoma. The x-axis represents weeks from baseline through treatment phases labeled Titraton and Maintenance, and the y-axis measures calcium levels from 8 to 16 mg/dL. Data points with error bars indicate changes in calcium during the study period.*

FDA Label Image

Figure4 (Figure4)

A line graph illustrating changes in calcium levels (mg/dL) over weeks during titration and maintenance phases for Cinacalcet. The y-axis shows calcium concentration ranging from 8 to 16 mg/dL, and the x-axis represents weeks from baseline (B) through week 80. Data points include error bars, and the number of patients at each time point is indicated below the x-axis.*

FDA Label Image

Structure (Structure)

Chemical structure of the active ingredient Cinacalcet hydrochloride, showing its molecular arrangement including trifluoromethyl group, aromatic rings, amine, and hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.